Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors

    Cancer Categories
    • Gastrointestinal (GI),Lung
    Karmanos Trial ID
    • 2019-098
    NCT ID
    • NCT03953235
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator
    • Philip
      Philip, M.D., Ph.D., F.R.C.P

      Oncology - Medical View Profile

    Objective:

    PRIMARY OBJECTIVE:
    • To assess the safety and tolerability of GRT-C903 (a ChAdV-based vaccine) and GRT-R904 (a SAM-LNP-based vaccine) in combination with immune checkpoint blockade, as assessed using Common Terminology Criteria for Adverse Events (CTCAE v5) in patients with advanced/metastatic MSS-CRC, NSCLC, PDA, as well as in other mutation-positive solid tumors.
    • Phase 2 and Expansion Cohorts: To assess the anti-tumor activity of GRT-C903 and GRT-R904 in combination with immune checkpoint blockade in patients with advanced/metastatic MSS-CRC, NSCLC, PDA, and other mutation-positive solid tumors as assessed by objective response rate (ORR) according to the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
    • To define (Phase 1) and confirm (Phase 2) the recommended Phase 2 dose (RP2D) of GRT-C903 and GRT-R904 administered in combination with checkpoint blockade.
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266